Physostigmine for Alzheimer's disease

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Trials

Background:

• Alzheimer's disease (AD) treatment primarily targets cholinergic transmission via acetylcholinesterase (AChE) inhibition.
• Physostigmine, an AChE inhibitor, has shown potential for memory improvement but is limited by a short half-life.
• Controlled-release formulations and skin patches have been developed to improve physostigmine's therapeutic utility in AD.

Purpose of the Study:

• To evaluate the efficacy of physostigmine in treating Alzheimer's disease.
• To assess the incidence and severity of adverse effects associated with physostigmine use in AD patients.

Main Methods:

• Systematic review of randomized, placebo-controlled trials of physostigmine in Alzheimer's disease patients.
• Searched Cochrane Controlled Trials Register for physostigmine and related terms.
• Data extraction and analysis included intention-to-treat analysis and estimation of mean differences and odds ratios.

Main Results:

• No significant benefits were observed with intravenous or conventional oral physostigmine.
• Controlled-release physostigmine showed modest improvements in ADAS-Cog and CGIC scores at 6 and 12 weeks in responders, but with significant adverse events and withdrawals.
• Fixed-dose controlled-release physostigmine in all-comer trials resulted in significantly higher withdrawal rates due to adverse events, including nausea, vomiting, and dizziness.

Conclusions:

• Evidence for physostigmine's effectiveness in the symptomatic treatment of Alzheimer's disease is limited.
• Despite formulation improvements, physostigmine demonstrates no convincing clinical benefit for AD.
• Common adverse effects associated with physostigmine treatment lead to high withdrawal rates, questioning its therapeutic value.